Physician profile
Mitchell A Lazar
NPI 1891720835
$358,278.18
in general payments reported to CMS, 2019-2025
3 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $48K · 2021: $49K · 2022: $90K · 2023: $57K · 2024: $27K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $99K · Travel and Lodging: $6,725 · Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $98,995.00 |
| Travel and Lodging | $6,725.07 |
| Food and Beverage | $1,455.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $353,098.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $3,784.50 | 2019 | |
| Novo Nordisk US Research & Development, INC. | $1,395.00 | 2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.